Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.
about
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura.Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 Deficiency.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw.Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model.Arsenicosis, possibly from contaminated groundwater, associated with noncirrhotic intrahepatic portal hypertension.
P2860
Q30441694-78A9490A-43AE-455B-BAA7-5ABC37FCDAC9Q33372348-7BDE9EF0-F23B-4100-B6D7-F452DAB8010AQ33373912-56E30812-11FF-4B39-A226-7BAA7714EC31Q33374597-393DE1B7-B1EE-4183-824A-A0720CA0B13AQ33376161-8B01F17F-2563-423F-8E9F-A1DD6DF102DDQ33377517-46917858-2A03-42CA-8460-8F62892F34F9Q33395323-5848D359-1FB5-4BCD-BC86-E363446438A7Q33401403-A3A9E606-F6B5-427A-A862-7F7B497A3E6EQ33402274-C60B5C2B-1066-46A4-B9D5-673C59D876ACQ33407886-C79C22E9-D9DE-4103-88EA-3444DC00885DQ33841435-FEB623BF-2052-4BA6-B622-62285A2AFDB3Q46808805-73A71B22-FB89-4F98-9D87-7BFDFE00C053Q50705094-6DD72180-6F7E-4111-9B0B-5AABDE1CDCCAQ53094414-BAECEEF8-6DA7-4540-B20A-36EE677BA22D
P2860
Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@ast
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@en
type
label
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@ast
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@en
prefLabel
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@ast
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@en
P2093
P2860
P1433
P1476
Coagulation factor levels in c ...... S-59) and ultraviolet A light.
@en
P2093
Andrew S Lawrie
Helen Yarranton
Ian J Mackie
Laurence Corash
Linda Pinkoski
Samuel J Machin
P2860
P304
P356
10.1111/J.1537-2995.2005.00551.X
P577
2005-09-01T00:00:00Z